Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Refractory Solid Tumors × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 3 Refractory Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Breast Neoplasms 1

Interventions

Sorafenib 3 pazopanib 2 verubulin 1 trifluridine tipiracil drug combination 1 irinotecan sucrosofate 1 Valproic Acid 1 Sunitinib 1 Sirolimus 1 Interleukin-27 1 Hydralazine 1 Erlotinib Hydrochloride 1 Azurin 1 Arsenic Trioxide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00404508 2006-11-28

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

National Institute of Cancerología

Phase 2 Completed

Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡